Skip to content

The use of punicalagin to improve leukemia treatments efficacy

A recent study has demonstrated that punicalagin possesses anti-leukemic effects, producing cancer cell death.

Leukemia is a type of blood cancer that begins in the bone marrow, the soft tissue in the center of bones where blood cells are made. In 2020, this cancer produced 311594 deaths worldwide. Treatments for leukemia include chemotherapy, stem cell transplantation, and targeted treatment of the disease. However, in the last years, natural products have been used to improve the efficacy of the treatment. Punicalagin is the main phenolic compound found in pomegranate peels and has several reported medical benefits, such as anti-inflammatory, antioxidant, and anticancer properties against several types of cancer.

Recently, Paweena Subkorn and co-workers at Mahidol University in Thailandia, have investigated the anti-leukemic effects and the mechanism of action of punicalagin against several leukemic cell lines. They have found that punicalagin decreased cell viability in a dose-dependent manner. In addition, punicalagin, in combination with the clinical used anti-leukemic drug daunorubicin, showed synergistic antitumor effects. The findings of this work reveal that punicalagin may assist in the creation of alternative and complementary treatments in the future.

Article: Punicalagin, a pomegranate compound, induces apoptosis and autophagy in acute leukemias.

previous arrow
next arrow